Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominick J Angiolillo

Showing results (541-550 of 761) with videos related to

Pageof 77
Sort By:
Thrombosis and Haemostasis|September 7, 2013
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathwaysOscar Ö Braun, Dominick J Angiolillo, Jose L Ferreiro, et al.
Cardiovascular Drugs and Therapy|June 19, 2008
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol designMarco Valgimigli, Gianluca Campo, Nicoletta de Cesare, et al.
European Heart Journal|February 6, 2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
JACC. Advances|February 4, 2026
Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor TherapyJean G Malavé, Cameron D Thomas, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|May 26, 2026
Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized TrialsMattia Galli, Mattia Vinciguerra, Claudio Laudani, et al.
Circulation. Cardiovascular Interventions|April 28, 2011
Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover studyJosé Luis Ferreiro, Masafumi Ueno, Salvatore D Tomasello, et al.
European Heart Journal|May 14, 2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trialAlan D Michelson, Andrew L Frelinger, Eugene Braunwald, et al.
Nature Reviews. Cardiology|January 23, 2026
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapiesMattia Galli, Antonio Abbate, Marc P Bonaca, et al.
Journal of the American College of Cardiology|June 6, 2006
Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) TrialPilar Jiménez-Quevedo, Manel Sabaté, Dominick J Angiolillo, et al.
Platelets|November 28, 2006
Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery diseaseEsther Bernardo, Dominick J Angiolillo, Celia Ramírez, et al.
Pageof 77

Showing results (541-550 of 761) with videos related to

Sort By:
Pageof 77
Thrombosis and Haemostasis|September 7, 2013
Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathwaysOscar Ö Braun, Dominick J Angiolillo, Jose L Ferreiro, et al.
Cardiovascular Drugs and Therapy|June 19, 2008
Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel (3T/2R). Rationale for the study and protocol designMarco Valgimigli, Gianluca Campo, Nicoletta de Cesare, et al.
European Heart Journal|February 6, 2016
A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized studyFabiana Rollini, Francesco Franchi, Jung Rae Cho, et al.
JACC. Advances|February 4, 2026
Impact of Area-Level Socioeconomic Deprivation on Post-PCI Outcomes Stratified by P2Y<sub>12</sub> Inhibitor TherapyJean G Malavé, Cameron D Thomas, Francesco Franchi, et al.
JACC. Cardiovascular Interventions|May 26, 2026
Oral Anticoagulation With or Without Antiplatelet Therapy in Chronic Coronary Syndrome: A Meta-Analysis of Randomized TrialsMattia Galli, Mattia Vinciguerra, Claudio Laudani, et al.
Circulation. Cardiovascular Interventions|April 28, 2011
Pharmacodynamic evaluation of pantoprazole therapy on clopidogrel effects: results of a prospective, randomized, crossover studyJosé Luis Ferreiro, Masafumi Ueno, Salvatore D Tomasello, et al.
European Heart Journal|May 14, 2009
Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trialAlan D Michelson, Andrew L Frelinger, Eugene Braunwald, et al.
Nature Reviews. Cardiology|January 23, 2026
Residual cardiovascular risk in coronary artery disease: from pathophysiology to established and novel therapiesMattia Galli, Antonio Abbate, Marc P Bonaca, et al.
Journal of the American College of Cardiology|June 6, 2006
Vascular effects of sirolimus-eluting versus bare-metal stents in diabetic patients: three-dimensional ultrasound results of the Diabetes and Sirolimus-Eluting Stent (DIABETES) TrialPilar Jiménez-Quevedo, Manel Sabaté, Dominick J Angiolillo, et al.
Platelets|November 28, 2006
Lack of association between gene sequence variations of platelet membrane receptors and aspirin responsiveness detected by the PFA-100 system in patients with coronary artery diseaseEsther Bernardo, Dominick J Angiolillo, Celia Ramírez, et al.
Pageof 77